The Asthma Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.
“Asthma Pipeline Insight, 2024“ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Asthma Market.
Some of the key takeaways from the Asthma Pipeline Report:
Companies across the globe are diligently working toward developing novel Asthma treatment therapies with a considerable amount of success over the years.
Asthma companies working in the treatment market are Landos Biopharma, Lanier Biotherapeutics, Kinaset therapeutics, AstraZeneca, KeyMed Biosciences, Sterna Biologics, Chia Tai Tianqing Pharmaceutical Group, GlaxoSmithKline, Areteia Therapeutics, and others, are developing therapies for the Asthma treatment
Emerging Asthma therapies in the different phases of clinical trials are- LABP-73, LNR 125.38, KN-002, AZD8630, CM326, SB010, TQC2731, GSK3511294, Dexpramipexole, and others are expected to have a significant impact on the Asthma market in the coming years.
In March 2024 Upstream Bio, a clinical-stage biotech company advancing new therapies to treat inflammation, announced the dosing of the first patients in its Phase 2 VALIANT clinical trial of verekitug (UPB-101) in patients with severe asthma.
In February 2024, Areteia Therapeutics announced the $75 million in additional Series A financing to support expansion of the current Phase III development program of dexpramipexole in eosinophilic asthma, bringing total Series A funding to $425 million. Viking Global Investors and Marshall Wace join the original syndicate of investors led by Bain Capital Life Sciences with participation from Access Biotechnology, GV, ARCH Venture Partners, Saturn Partners, Sanofi, Maverick Capital, and Population Health Partners
In October 2023, Aiolos Bio announced that it raised $245 million in Series A funding. Atlas Venture, Bain Capital Life Sciences, Forbion Capital Partners and Sofinnova Investments led the round, with additional investment from RA Capital Management. Aiolos plans to use the funds for phase 2 clinical trials of its lead drug candidate, AIO-001, for moderate-to-severe asthma patients.
In January 2023, Areteia Therapeutics initiated a randomized, double-blind, placebocontrolled, parallel-group study to assess the efficacy, safety, and tolerability of Dexpramipexole administered orally for 24 weeks in participants with Eosinophilic Asthma. The trial is currently recruiting the participants and is anticipated to be completed in March 2025 with an enrollment of 550 participants.
Asthma Overview
Asthma is a chronic respiratory condition characterized by inflammation and narrowing of the airways, which can lead to symptoms such as wheezing, coughing, chest tightness, and shortness of breath.
Get a Free Sample PDF Report to know more about Asthma Pipeline Therapeutic Assessment-
https://www.delveinsight.com/report-store/asthma-pipeline-insight
Emerging Asthma Drugs Under Different Phases of Clinical Development Include:
LABP-73: Landos Biopharma
LNR 125.38: Lanier Biotherapeutics
KN-002: Kinaset therapeutics
AZD8630: AstraZeneca
CM326: KeyMed Biosciences
SB010: Sterna Biologics
TQC2731: Chia Tai Tianqing Pharmaceutical Group
GSK3511294: GlaxoSmithKline
Dexpramipexole: Areteia Therapeutics
Asthma Route of Administration
Asthma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
Oral
Parenteral
Intravenous
Subcutaneous
Topical
Asthma Molecule Type
Asthma Products have been categorized under various Molecule types, such as
Monoclonal Antibody
Peptides
Polymer
Small molecule
Gene therapy
Asthma Pipeline Therapeutics Assessment
Asthma Assessment by Product Type
Asthma By Stage and Product Type
Asthma Assessment by Route of Administration
Asthma By Stage and Route of Administration
Asthma Assessment by Molecule Type
Asthma by Stage and Molecule Type
DelveInsight’s Asthma Report covers around 90+ products under different phases of clinical development like
Late-stage products (Phase III)
Mid-stage products (Phase II)
Early-stage product (Phase I)
Pre-clinical and Discovery stage candidates
Discontinued & Inactive candidates
Route of Administration
Further Asthma product details are provided in the report. Download the Asthma pipeline report to learn more about the emerging Asthma therapies
Some of the key companies in the Asthma Therapeutics Market include:
Key companies developing therapies for Asthma are – AstraZeneca PLC, Boehringer Ingelheim GmbH, GlaxoSmithKline PLC, Novartis AG, F. Hoffmann-La Roche Ltd, Pfizer Inc., Grifols SA, Merck & Co. Inc., Sanofi SA, Sumitomo Dainippon Pharma Co. Ltd, Teva Pharmaceutical Industries Ltd, Chiesi Farmaceutici SpA, and others.
Asthma Pipeline Analysis:
The Asthma pipeline report provides insights into
The report provides detailed insights about companies that are developing therapies for the treatment of Asthma with aggregate therapies developed by each company for the same.
It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Asthma Treatment.
Asthma key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
Asthma Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Asthma market.
The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.
Download Sample PDF Report to know more about Asthma drugs and therapies
Asthma Pipeline Market Drivers
The rising global prevalence of asthma presents a substantial market driver as it fuels demand for asthma management products, including medications, inhalers, and respiratory devices.
Asthma Pipeline Market Barriers
The high cost of asthma medications serves as a barrier by limiting accessibility for patients, particularly in regions with lower socioeconomic status or inadequate healthcare coverage. This barrier hampers treatment adherence, exacerbates health disparities.
Scope of Asthma Pipeline Drug Insight
Coverage: Global
Key Asthma Companies: Landos Biopharma, Lanier Biotherapeutics, Kinaset therapeutics, AstraZeneca, KeyMed Biosciences, Sterna Biologics, Chia Tai Tianqing Pharmaceutical Group, GlaxoSmithKline, Areteia Therapeutics, and others
Key Asthma Therapies: LABP-73, LNR 125.38, KN-002, AZD8630, CM326, SB010, TQC2731, GSK3511294, Dexpramipexole, and others
Asthma Therapeutic Assessment: Asthma current marketed and Asthma emerging therapies
Asthma Market Dynamics: Asthma market drivers and Asthma market barriers
Request for Sample PDF Report for Asthma Pipeline Assessment and clinical trials
Table of Contents
1. Asthma Report Introduction
2. Asthma Executive Summary
3. Asthma Overview
4. Asthma- Analytical Perspective In-depth Commercial Assessment
5. Asthma Pipeline Therapeutics
6. Asthma Late Stage Products (Phase II/III)
7. Asthma Mid Stage Products (Phase II)
8. Asthma Early Stage Products (Phase I)
9. Asthma Preclinical Stage Products
10. Asthma Therapeutics Assessment
11. Asthma Inactive Products
12. Company-University Collaborations (Licensing/Partnering) Analysis
13. Asthma Key Companies
14. Asthma Key Products
15. Asthma Unmet Needs
16 . Asthma Market Drivers and Barriers
17. Asthma Future Perspectives and Conclusion
18. Asthma Analyst Views
19. Appendix
20. About DelveInsight
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.
Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/
